following a full submission
edoxaban (Lixiana®) is accepted for use within NHS Scotland.
Indication under review: Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.
One phase III study showed non-inferiority of edoxaban versus a vitamin K antagonist for venous thromboembolism recurrence in patients who had received at least five days treatment with low molecular weight heparin or unfractionated heparin. Edoxaban was also associated with a significant reduction in the risk of major and clinically relevant non-major bleeding (composite endpoint).
|Drug Name:||edoxaban (Lixiana)|
|SMC Drug ID:||1090/15|
|Manufacturer:||Daiichi Sankyo UK Ltd|
|Indication:||Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.|
|Sub Category:||2.8 Anticoagulants and protamine|
|Submission Type:||Full submission|
|Date Advice Published:||9 November 2015|